An analysis of claims data from pharmacies in the USA shows that only one quarter of patients using Novo Nordisk's Wegovy or Ozempic for obesity treatment continued to adhere to the medication after two years. The analysis also showed a steady decline in medication usage over time. The analysis did not include the reasons why patients stopped using the medication. However, it does provide a longer-term perspective on patients' real experiences taking medication, whereas previous studies focused only on one year or shorter-term medication use. The fact that many patients may stop taking weight-loss drugs shortly after starting them is affecting the debate on the cost of these drugs for patients, employers, and government healthcare plans. Wegovy and similar drugs may cost more than $1,000 per month and might need long-term use to produce significant benefits. Recently, U.S. President Biden and other government officials criticized the prices of these drugs in the USA, saying that if only half of obese adults use these drugs, they could cost the U.S. $411 billion per year. This is more than $5 billion more than all prescription drug costs paid by Americans in 2022.